Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal



Fleeman, Nigel ORCID: 0000-0002-4637-9779, Abdulla, Ahmed, Bagust, Adrian ORCID: 0000-0002-2142-5767, Beale, Sophie ORCID: 0000-0003-0164-103X, Richardson, Marty, Stainthorpe, Angela ORCID: 0000-0002-2531-9371, Boland, Angela, Kotas, Eleanor, McEntee, Joanne and Palmer, Daniel ORCID: 0000-0002-7147-5703
(2018) Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36 (3). 289 - 299.

This is the latest version of this item.

[img] Text
PE_nal-iri_revised_proof-read.docx - Accepted Version

Download (157kB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 05 Dec 2017 10:29
Last Modified: 12 Oct 2021 11:28
DOI: 10.1007/s40273-017-0592-3
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3013557

Available Versions of this Item